Movement Alert｜Biogen Rises 5.86% in Regular Trading, Suspends Most Legacy Apellis Research Programs to Focus on Core Pipeline

Market Focus06-26 23:02

On June 26, Biogen rose 5.86% in regular trading, trading at $213.79/share, with turnover of approximately $101 million. The stock rallied after the company announced a major R&D strategy overhaul.

On the news front, Biogen disclosed its decision to suspend or terminate investment in the vast majority of legacy Apellis research programs. The company is conducting a comprehensive review of the former Apellis clinical and preclinical portfolio to assess strategic alignment. The market interpreted this as a proactive move to optimize R&D spending and sharpen focus on higher-potential core pipelines, improving capital allocation efficiency.

This strategic pivot follows Biogen's completion of the Apellis acquisition earlier this year and its separate agreement to acquire RayThera for up to $1 billion to expand its immunology pipeline. In Q1, the company posted adjusted EPS of $3.57, significantly beating the consensus estimate of $3.01, while its Alzheimer's drug Leqembi saw sales surge 74% year-over-year. Multiple analysts maintain overweight ratings, with Goldman Sachs targeting $250 and RBC Capital targeting $222.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1184546238?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-26 23:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184546238","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Biogen Rises 5.86% in Regular Trading, Suspends Most Legacy Apellis Research Programs to Focus on Core Pipeline","media":"Market Focus","content":"<p><p>On June 26, Biogen rose 5.86% in regular trading, trading at $213.79/share, with turnover of approximately $101 million. The stock rallied after the company announced a major R&D strategy overhaul.</p><p>On the news front, Biogen disclosed its decision to suspend or terminate investment in the vast majority of legacy Apellis research programs. The company is conducting a comprehensive review of the former Apellis clinical and preclinical portfolio to assess strategic alignment. The market interpreted this as a proactive move to optimize R&D spending and sharpen focus on higher-potential core pipelines, improving capital allocation efficiency.</p><p>This strategic pivot follows Biogen's completion of the Apellis acquisition earlier this year and its separate agreement to acquire RayThera for up to $1 billion to expand its immunology pipeline. In Q1, the company posted adjusted EPS of $3.57, significantly beating the consensus estimate of $3.01, while its Alzheimer's drug Leqembi saw sales surge 74% year-over-year. Multiple analysts maintain overweight ratings, with Goldman Sachs targeting $250 and RBC Capital targeting $222.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Biogen Rises 5.86% in Regular Trading, Suspends Most Legacy Apellis Research Programs to Focus on Core Pipeline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Biogen Rises 5.86% in Regular Trading, Suspends Most Legacy Apellis Research Programs to Focus on Core Pipeline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-26 23:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 26, Biogen rose 5.86% in regular trading, trading at $213.79/share, with turnover of approximately $101 million. The stock rallied after the company announced a major R&D strategy overhaul.</p><p>On the news front, Biogen disclosed its decision to suspend or terminate investment in the vast majority of legacy Apellis research programs. The company is conducting a comprehensive review of the former Apellis clinical and preclinical portfolio to assess strategic alignment. The market interpreted this as a proactive move to optimize R&D spending and sharpen focus on higher-potential core pipelines, improving capital allocation efficiency.</p><p>This strategic pivot follows Biogen's completion of the Apellis acquisition earlier this year and its separate agreement to acquire RayThera for up to $1 billion to expand its immunology pipeline. In Q1, the company posted adjusted EPS of $3.57, significantly beating the consensus estimate of $3.01, while its Alzheimer's drug Leqembi saw sales surge 74% year-over-year. Multiple analysts maintain overweight ratings, with Goldman Sachs targeting $250 and RBC Capital targeting $222.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIIB","symbol_name":"渤健公司","start_time":0,"source_url":"","article_id":"1184546238","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184546238","pubTimestamp":1782486165,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 26, Biogen rose 5.86% in regular trading, trading at $213.79/share, with turnover of approximately $101 million. The stock rallied after the company announced a major R&D strategy overhaul.On...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BIIB":"渤健公司"},"translate_title":"动向提示|百健(Biogen)常规交易涨5.86%暂停大部分遗留Apellis研究项目专注核心管线","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1},"content_text":"On June 26, Biogen rose 5.86% in regular trading, trading at $213.79/share, with turnover of approximately $101 million. The stock rallied after the company announced a major R&D strategy overhaul.On the news front, Biogen disclosed its decision to suspend or terminate investment in the vast majority of legacy Apellis research programs. The company is conducting a comprehensive review of the former Apellis clinical and preclinical portfolio to assess strategic alignment. The market interpreted this as a proactive move to optimize R&D spending and sharpen focus on higher-potential core pipelines, improving capital allocation efficiency.This strategic pivot follows Biogen's completion of the Apellis acquisition earlier this year and its separate agreement to acquire RayThera for up to $1 billion to expand its immunology pipeline. In Q1, the company posted adjusted EPS of $3.57, significantly beating the consensus estimate of $3.01, while its Alzheimer's drug Leqembi saw sales surge 74% year-over-year. Multiple analysts maintain overweight ratings, with Goldman Sachs targeting $250 and RBC Capital targeting $222.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1184546238","isCrawlerRequest":true}